NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET FORECAST 2018-2026
KEY FINDINGS
The prevalence of blindness and vision impairment and other eye-related disorders is expected to increase rapidly among all age group, gender and racial group in North America. As a result, the North America ophthalmic drugs and devices market is expected to progress at a CAGR of 5.91% over the forecast period of 2018-2026.
MARKET INSIGHTS
Increasing demand for intraocular lenses and phacoemulsification devices is presenting this market with amazing growth opportunities. Increasing pharmaceuticals market is the key driver for the US ophthalmic drug market. Also, as the prevalence of eye disorders in the US is increasing, the government has started various policies for increasing the awareness of the same and is also investing in various reimbursement policies and healthcare infrastructure to improve the quality of service and life expectancy of people living in the US. In terms of CAGR, Canada is expected to outpace the US and Mexico ophthalmic drugs and devices market. Retinal disorders are spreading widely across this country, mostly because of the age-related diseases.
COMPETITIVE INSIGHTS
Some of the established companies in this region include GlaxoSmithKline, Pfizer, Santen Pharmaceutical Co Ltd, Allergan Inc, Johnson & Johnson Inc, Novartis International Ag, Valent Pharmaceuticals International Inc, Ziemer Group Holding Ag, Bayer, and Roche Holding Ag.
The prevalence of blindness and vision impairment and other eye-related disorders is expected to increase rapidly among all age group, gender and racial group in North America. As a result, the North America ophthalmic drugs and devices market is expected to progress at a CAGR of 5.91% over the forecast period of 2018-2026.
MARKET INSIGHTS
Increasing demand for intraocular lenses and phacoemulsification devices is presenting this market with amazing growth opportunities. Increasing pharmaceuticals market is the key driver for the US ophthalmic drug market. Also, as the prevalence of eye disorders in the US is increasing, the government has started various policies for increasing the awareness of the same and is also investing in various reimbursement policies and healthcare infrastructure to improve the quality of service and life expectancy of people living in the US. In terms of CAGR, Canada is expected to outpace the US and Mexico ophthalmic drugs and devices market. Retinal disorders are spreading widely across this country, mostly because of the age-related diseases.
COMPETITIVE INSIGHTS
Some of the established companies in this region include GlaxoSmithKline, Pfizer, Santen Pharmaceutical Co Ltd, Allergan Inc, Johnson & Johnson Inc, Novartis International Ag, Valent Pharmaceuticals International Inc, Ziemer Group Holding Ag, Bayer, and Roche Holding Ag.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. VISION CARE DEVICES ARE DOMINATING THE MARKET
3.2.2. GLAUCOMA DRUGS ARE MAJORLY USED
3.2.3. RISING PREVALENCE OF EYE RELATED DISEASES
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASING PREVALENCE OF DIABETES INCREASES THE PROBABILITY OF OPHTHALMIC DISORDERS
4.1.2. TECHNOLOGICAL ADVANCEMENT
4.1.3. INCREASE IN HEALTHCARE EXPENDITURE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUG APPROVALS
4.2.3. AWARENESS RELATED TO OPHTHALMOLOGY DRUGS ARE LOW
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
4.3.2. INCREASING DEMAND FOR INTRAOCULAR LENSES AND PHACOEMULSIFICATION DEVICES
4.4. MARKET CHALLENGES
4.4.1. VARIOUS RISK AND COMPLICATIONS ASSOCIATED WITH THE TREATMENT OF OCULAR DISEASES
5. MARKET SEGMENTATION
5.1. MARKET BY DRUGS AND DEVICES 2018-2026
5.1.1. DEVICES
5.1.1.1. DIAGNOSTIC & MONITORING EQUIPMENT
5.1.1.1.1. OPTICAL COHERENCE TOMOGRAPHY
5.1.1.1.2. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
5.1.1.1.3. FUNDUS CAMERA MARKET
5.1.1.1.4. OPHTHALMOSCOPES
5.1.1.1.5. RETINOSCOPE
5.1.1.1.6. PACHYMETER
5.1.1.1.7. WAVEFRONT ABERROMETERS
5.1.1.1.8. PERIMETERS/VISUAL FIELD ANALYZER
5.1.1.1.9. AUTOREFRACTORS/PHOROPTER
5.1.1.1.10. SPECULAR MICROSCOPE
5.1.1.1.11. CORNEAL TOPOGRAPHERS
5.1.1.1.12. OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET
5.1.1.2. SURGERY DEVICE
5.1.1.2.1. CATARACT SURGERY DEVICES
5.1.1.2.2. GLAUCOMA SURGERY DEVICES
5.1.1.2.3. REFRACTIVE SURGERY DEVICES
5.1.1.2.4. VITREORETINAL SURGERY DEVICES
5.1.1.3. VISION CARE
5.1.2. DRUGS
5.1.2.1. GLAUCOMA DRUG
5.1.2.2. RETINAL DISORDER DRUG
5.1.2.3. DRY EYE DRUG
5.1.2.4. ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. BARGAINING POWER OF BUYERS
6.1.2. BARGAINING POWER OF SUPPLIER
6.1.3. THREATS OF NEW ENTRANTS
6.1.4. THREATS OF SUBSTITUTES
6.1.5. COMPETITIVE RIVALRY
6.2. VALUE CHAIN ANALYSIS
6.2.1. RESEARCH AND DEVELOPMENT
6.2.2. MANUFACTURING
6.2.3. DISTRIBUTORS
6.2.4. END USERS
6.3. KEY BUYING CRITERIA
6.3.1. COST
6.3.2. EFFICACY
6.3.3. ACCESSIBILITY
6.3.4. INNOVATION
6.4. SUPPLY CHAIN ANALYSIS
6.4.1. SUPPLIERS
6.4.2. MANUFACTURERS
6.4.3. DISTRIBUTORS AND RETAILERS
6.4.4. END USERS
6.5. REGULATORY FRAMEWORK
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
8. COMPANY PROFILES
8.1. COMPETITIVE ANALYSIS
8.1.1. MARKET SHARE ANALYSIS
8.1.2. TOP COMPANIES
8.1.2.1. ESSILOR INTERNATIONAL S.A. (FRANCE)
8.1.2.2. JOHNSON & JOHNSON INC. (U.S.)
8.1.2.3. ALLERGAN PLC (U.S.)
8.1.2.4. NOVARTIS INTERNATIONAL AG (SWITZERLAND)
8.1.2.5. VALENT PHARMACEUTICALS INTERNATIONAL INC. (U.S.)
8.2. ALLERGAN INC.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT & SERVICES
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. BAYER
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT & SERVICES
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. CARL ZEISS AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC INITIATIVE
8.5. ESSILOR INTERNATIONAL S.A.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT & SERVICES
8.5.3. SWOT ANALYSIS
8.5.4. STRATEGIC INITIATIVE
8.6. GLAXOSMITHKLINE
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SWOT ANALYSIS
8.7. JOHNSON & JOHNSON INC.
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. NOVARTIS INTERNATIONAL AG
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. PFIZER
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. SANTEN PHARMACEUTICAL CO., LTD.
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.11.4. STRATEGIC INITIATIVE
8.12. SUN PHARMACEUTICALS INDUSTRIES, LTD
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVE
8.13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVE
8.14. ZIEMER GROUP HOLDING AG
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
TABLE 2 PREVALENCE OF EYE DISEASES IN US 2014 & 2030
TABLE 3 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 4 SELECTED LIST OF GLAUCOMA DRUGS IN LATE-STAGE CLINICAL TRIALS
TABLE 5 EYE DRUGS GONE OFF-PATENT
TABLE 6 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2018-2026 ($ MILLION)
TABLE 7 NORTH AMERICA DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
TABLE 8 NORTH AMERICA DEVICES MARKET IN DIAGNOSTIC & MONITORING EQUIPMENT BY TYPES 2018-2026 ($ MILLION)
TABLE 9 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPTICAL COHERENCE TOMOGRAPHY 2018-2026 ($ MILLION)
TABLE 10 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMIC ULTRASOUND IMAGING SYSTEMS 2018-2026 ($ MILLION)
TABLE 11 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN FUNDUS CAMERA MARKET 2018-2026 ($ MILLION)
TABLE 12 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMOSCOPES 2018-2026 ($ MILLION)
TABLE 13 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN RETINOSCOPE 2018-2026 ($ MILLION)
TABLE 14 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PACHYMETER 2018-2026 ($ MILLION)
TABLE 15 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN WAVEFRONT ABERROMETERS 2018-2026 ($ MILLION)
TABLE 16 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PERIMETERS/VISUAL FIELD ANALYZER 2018-2026 ($ MILLION)
TABLE 17 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN AUTOREFRACTORS/PHOROPTER 2018-2026 ($ MILLION)
TABLE 18 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN SPECULAR MICROSCOPE 2018-2026 ($ MILLION)
TABLE 19 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN CORNEAL TOPOGRAPHERS 2018-2026 ($ MILLION)
TABLE 20 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2018-2026 ($ MILLION)
TABLE 21 NORTH AMERICA DEVICES MARKET IN SURGERY DEVICE BY TYPES 2018-2026 ($ MILLION)
TABLE 22 NORTH AMERICA SURGERY DEVICES MARKET IN CATARACT SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 23 NORTH AMERICA SURGERY DEVICES MARKET IN GLAUCOMA SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 24 NORTH AMERICA SURGERY DEVICES MARKET IN REFRACTIVE SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 25 NORTH AMERICA SURGERY DEVICES MARKET IN VITREORETINAL SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 26 NORTH AMERICA DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
TABLE 27 NORTH AMERICA DRUGS AND DEVICES MARKET IN DRUGS BY TYPES 2018-2026 ($ MILLION)
TABLE 28 NORTH AMERICA DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
TABLE 29 NORTH AMERICA DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
TABLE 30 NORTH AMERICA DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
TABLE 31 NORTH AMERICA DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
TABLE 32 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
FIGURE 2 NORTH AMERICA DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
FIGURE 3 NORTH AMERICA DEVICES MARKET DIAGNOSTIC & MONITORING EQUIPMENT IN 2018-2026 ($ MILLION)
FIGURE 4 NORTH AMERICA DEVICES MARKET IN SURGERY DEVICE 2018-2026 ($ MILLION)
FIGURE 5 NORTH AMERICA DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
FIGURE 6 NORTH AMERICA DRUGS AND DEVICES MARKET IN DRUGS 2018-2026 ($ MILLION)
FIGURE 7 NORTH AMERICA DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
FIGURE 8 NORTH AMERICA DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
FIGURE 9 NORTH AMERICA DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
FIGURE 10 NORTH AMERICA DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
FIGURE 11 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 12 THE UNITED STATES OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 13 CANADA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 14 OPHTHALMOLOGY DEVICES COMPANY MARKET SHARE 2017 (%)
FIGURE 15 OPHTHALMOLOGY DRUGS COMPANY MARKET SHARE 2017 (%)
COMPANIES MENTIONED
2. ALLERGAN INC.
3. BAYER
4. CARL ZEISS AG
5. ESSILOR INTERNATIONAL S.A.
6. GLAXOSMITHKLINE
7. JOHNSON & JOHNSON INC.
8. NOVARTIS INTERNATIONAL AG
9. PFIZER
10. ROCHE HOLDING AG
11. SANTEN PHARMACEUTICAL CO., LTD.
12. SUN PHARMACEUTICALS INDUSTRIES, LTD
13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
14. ZIEMER GROUP HOLDING AG
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. VISION CARE DEVICES ARE DOMINATING THE MARKET
3.2.2. GLAUCOMA DRUGS ARE MAJORLY USED
3.2.3. RISING PREVALENCE OF EYE RELATED DISEASES
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASING PREVALENCE OF DIABETES INCREASES THE PROBABILITY OF OPHTHALMIC DISORDERS
4.1.2. TECHNOLOGICAL ADVANCEMENT
4.1.3. INCREASE IN HEALTHCARE EXPENDITURE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUG APPROVALS
4.2.3. AWARENESS RELATED TO OPHTHALMOLOGY DRUGS ARE LOW
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
4.3.2. INCREASING DEMAND FOR INTRAOCULAR LENSES AND PHACOEMULSIFICATION DEVICES
4.4. MARKET CHALLENGES
4.4.1. VARIOUS RISK AND COMPLICATIONS ASSOCIATED WITH THE TREATMENT OF OCULAR DISEASES
5. MARKET SEGMENTATION
5.1. MARKET BY DRUGS AND DEVICES 2018-2026
5.1.1. DEVICES
5.1.1.1. DIAGNOSTIC & MONITORING EQUIPMENT
5.1.1.1.1. OPTICAL COHERENCE TOMOGRAPHY
5.1.1.1.2. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
5.1.1.1.3. FUNDUS CAMERA MARKET
5.1.1.1.4. OPHTHALMOSCOPES
5.1.1.1.5. RETINOSCOPE
5.1.1.1.6. PACHYMETER
5.1.1.1.7. WAVEFRONT ABERROMETERS
5.1.1.1.8. PERIMETERS/VISUAL FIELD ANALYZER
5.1.1.1.9. AUTOREFRACTORS/PHOROPTER
5.1.1.1.10. SPECULAR MICROSCOPE
5.1.1.1.11. CORNEAL TOPOGRAPHERS
5.1.1.1.12. OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET
5.1.1.2. SURGERY DEVICE
5.1.1.2.1. CATARACT SURGERY DEVICES
5.1.1.2.2. GLAUCOMA SURGERY DEVICES
5.1.1.2.3. REFRACTIVE SURGERY DEVICES
5.1.1.2.4. VITREORETINAL SURGERY DEVICES
5.1.1.3. VISION CARE
5.1.2. DRUGS
5.1.2.1. GLAUCOMA DRUG
5.1.2.2. RETINAL DISORDER DRUG
5.1.2.3. DRY EYE DRUG
5.1.2.4. ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. BARGAINING POWER OF BUYERS
6.1.2. BARGAINING POWER OF SUPPLIER
6.1.3. THREATS OF NEW ENTRANTS
6.1.4. THREATS OF SUBSTITUTES
6.1.5. COMPETITIVE RIVALRY
6.2. VALUE CHAIN ANALYSIS
6.2.1. RESEARCH AND DEVELOPMENT
6.2.2. MANUFACTURING
6.2.3. DISTRIBUTORS
6.2.4. END USERS
6.3. KEY BUYING CRITERIA
6.3.1. COST
6.3.2. EFFICACY
6.3.3. ACCESSIBILITY
6.3.4. INNOVATION
6.4. SUPPLY CHAIN ANALYSIS
6.4.1. SUPPLIERS
6.4.2. MANUFACTURERS
6.4.3. DISTRIBUTORS AND RETAILERS
6.4.4. END USERS
6.5. REGULATORY FRAMEWORK
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
8. COMPANY PROFILES
8.1. COMPETITIVE ANALYSIS
8.1.1. MARKET SHARE ANALYSIS
8.1.2. TOP COMPANIES
8.1.2.1. ESSILOR INTERNATIONAL S.A. (FRANCE)
8.1.2.2. JOHNSON & JOHNSON INC. (U.S.)
8.1.2.3. ALLERGAN PLC (U.S.)
8.1.2.4. NOVARTIS INTERNATIONAL AG (SWITZERLAND)
8.1.2.5. VALENT PHARMACEUTICALS INTERNATIONAL INC. (U.S.)
8.2. ALLERGAN INC.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT & SERVICES
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. BAYER
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT & SERVICES
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. CARL ZEISS AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC INITIATIVE
8.5. ESSILOR INTERNATIONAL S.A.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT & SERVICES
8.5.3. SWOT ANALYSIS
8.5.4. STRATEGIC INITIATIVE
8.6. GLAXOSMITHKLINE
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SWOT ANALYSIS
8.7. JOHNSON & JOHNSON INC.
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. NOVARTIS INTERNATIONAL AG
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. PFIZER
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. SANTEN PHARMACEUTICAL CO., LTD.
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.11.4. STRATEGIC INITIATIVE
8.12. SUN PHARMACEUTICALS INDUSTRIES, LTD
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVE
8.13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVE
8.14. ZIEMER GROUP HOLDING AG
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
TABLE 2 PREVALENCE OF EYE DISEASES IN US 2014 & 2030
TABLE 3 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 4 SELECTED LIST OF GLAUCOMA DRUGS IN LATE-STAGE CLINICAL TRIALS
TABLE 5 EYE DRUGS GONE OFF-PATENT
TABLE 6 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2018-2026 ($ MILLION)
TABLE 7 NORTH AMERICA DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
TABLE 8 NORTH AMERICA DEVICES MARKET IN DIAGNOSTIC & MONITORING EQUIPMENT BY TYPES 2018-2026 ($ MILLION)
TABLE 9 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPTICAL COHERENCE TOMOGRAPHY 2018-2026 ($ MILLION)
TABLE 10 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMIC ULTRASOUND IMAGING SYSTEMS 2018-2026 ($ MILLION)
TABLE 11 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN FUNDUS CAMERA MARKET 2018-2026 ($ MILLION)
TABLE 12 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMOSCOPES 2018-2026 ($ MILLION)
TABLE 13 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN RETINOSCOPE 2018-2026 ($ MILLION)
TABLE 14 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PACHYMETER 2018-2026 ($ MILLION)
TABLE 15 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN WAVEFRONT ABERROMETERS 2018-2026 ($ MILLION)
TABLE 16 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PERIMETERS/VISUAL FIELD ANALYZER 2018-2026 ($ MILLION)
TABLE 17 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN AUTOREFRACTORS/PHOROPTER 2018-2026 ($ MILLION)
TABLE 18 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN SPECULAR MICROSCOPE 2018-2026 ($ MILLION)
TABLE 19 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN CORNEAL TOPOGRAPHERS 2018-2026 ($ MILLION)
TABLE 20 NORTH AMERICA DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2018-2026 ($ MILLION)
TABLE 21 NORTH AMERICA DEVICES MARKET IN SURGERY DEVICE BY TYPES 2018-2026 ($ MILLION)
TABLE 22 NORTH AMERICA SURGERY DEVICES MARKET IN CATARACT SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 23 NORTH AMERICA SURGERY DEVICES MARKET IN GLAUCOMA SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 24 NORTH AMERICA SURGERY DEVICES MARKET IN REFRACTIVE SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 25 NORTH AMERICA SURGERY DEVICES MARKET IN VITREORETINAL SURGERY DEVICES 2018-2026 ($ MILLION)
TABLE 26 NORTH AMERICA DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
TABLE 27 NORTH AMERICA DRUGS AND DEVICES MARKET IN DRUGS BY TYPES 2018-2026 ($ MILLION)
TABLE 28 NORTH AMERICA DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
TABLE 29 NORTH AMERICA DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
TABLE 30 NORTH AMERICA DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
TABLE 31 NORTH AMERICA DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
TABLE 32 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026
FIGURE 2 NORTH AMERICA DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
FIGURE 3 NORTH AMERICA DEVICES MARKET DIAGNOSTIC & MONITORING EQUIPMENT IN 2018-2026 ($ MILLION)
FIGURE 4 NORTH AMERICA DEVICES MARKET IN SURGERY DEVICE 2018-2026 ($ MILLION)
FIGURE 5 NORTH AMERICA DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
FIGURE 6 NORTH AMERICA DRUGS AND DEVICES MARKET IN DRUGS 2018-2026 ($ MILLION)
FIGURE 7 NORTH AMERICA DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
FIGURE 8 NORTH AMERICA DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
FIGURE 9 NORTH AMERICA DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
FIGURE 10 NORTH AMERICA DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
FIGURE 11 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 12 THE UNITED STATES OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 13 CANADA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 14 OPHTHALMOLOGY DEVICES COMPANY MARKET SHARE 2017 (%)
FIGURE 15 OPHTHALMOLOGY DRUGS COMPANY MARKET SHARE 2017 (%)
COMPANIES MENTIONED
2. ALLERGAN INC.
3. BAYER
4. CARL ZEISS AG
5. ESSILOR INTERNATIONAL S.A.
6. GLAXOSMITHKLINE
7. JOHNSON & JOHNSON INC.
8. NOVARTIS INTERNATIONAL AG
9. PFIZER
10. ROCHE HOLDING AG
11. SANTEN PHARMACEUTICAL CO., LTD.
12. SUN PHARMACEUTICALS INDUSTRIES, LTD
13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
14. ZIEMER GROUP HOLDING AG
